Dynamo Platform
Motion-based drug design platform for discovering therapeutics
Platform · OtherCompany source
Company profile
About Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine company transforming drug discovery through its proprietary Dynamo platform. Unlike traditional drug discovery approaches that rely on static protein structures, Relay's technology enables visualization of protein motion in high-definition, allowing the company to more effectively target proteins that have been previously intractable or inadequately drugged. The company integrates leading-edge experimental and computational approaches to advance a pipeline of promising therapeutic candidates with an initial focus on precision oncology and genetic disease. Based in Cambridge, Massachusetts, Relay Therapeutics is a publicly traded company committed to bringing life-changing medicines to patients. The company's team is highly integrated, collaborative, and entrepreneurial, driven by a personal mission to develop treatments for diseases that have impacted many team members personally. Relay's motion-based drug design approach represents a fundamental shift in how drug discovery is conducted, creating new possibilities for targeting the 'undruggable' and advancing precision medicine.
Company description Relay Therapeutics official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Relay Therapeutics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- genetic disease
- precision oncology
Who it serves
- Healthcare Providers
- Patients
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Advancing pipeline of therapeutic candidates in clinical development
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Cryptic small-molecule binding sites in the ARID1B DNA-binding domain.Proceedings of the National Academy of Sciences of the United States of America · Aug 18, 2026
Nanoscale Direct-to-Biology Optimization of Cdk2 Inhibitors.Journal of medicinal chemistry · Apr 23, 2026
CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2.Journal of chemical information and modeling · Feb 9, 2026
DNA-Encoded Chemical Library Screening with Target Titration Analysis: DELTA.Journal of medicinal chemistry · Jan 22, 2026
Correction: Enhanced Thompson sampling by roulette wheel selection for screening ultralarge combinatorial libraries.Journal of cheminformatics · Oct 21, 2025
Enhanced Thompson sampling by roulette wheel selection for screening ultralarge combinatorial libraries.Journal of cheminformatics · Oct 13, 2025
Clinical validation
Clinical-trial records
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · Sponsor · RECRUITING
Early Childhood Obesity Programming by Intrauterine Growth RestrictionNCT03402139 · Sponsor · COMPLETED
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)NCT06789913 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Relay Therapeutics
Recent articles published on Relay Therapeutics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.